Climb Bio, Inc. (CLYM) News
Track canonical SquawkNews coverage tagged to CLYM, Climb Bio, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 17 indexed stories across 6 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
CLYM: Advancing two antibody assets in renal and autoimmune diseases with pivotal trials and robust data flow
Two antibody programs are advancing in immune-mediated diseases, with CLYM116 showing best-in-class 12-week dosing and safety in IgAN, and budoprutug demonstrating strong efficacy in pMN and ITP. Multiple pivotal trials
EQUITY | Sep 09, 2026, 10:55 PM UTC
L
CLYM: Advancing two antibody assets in renal and autoimmune diseases, with pivotal trials ahead
Two antibody programs are advancing in immune-mediated diseases, with CLYM-116 showing best-in-class potential in IgAN and budoprutug demonstrating strong efficacy in PMN and ITP. Multiple pivotal trials and data readout
EQUITY | Sep 09, 2026, 09:30 PM UTC
L
Oppenheimer maintains Outperform on Climb Bio; PT raised to $25
Oppenheimer maintained its Outperform rating on Climb Bio and raised its price target to $25.00 per share from $18.00, per Benzinga.
EQUITY | Sep 08, 2026, 05:05 PM UTC
L
Climb Bio PT raised to $32 from $20 by BTIG
BTIG raised its price target for Climb Bio to $32.00 per share from $20.00, while maintaining a Buy rating.
EQUITY | Sep 03, 2026, 06:24 PM UTC
L
CLYM PT raised by Baird; maintained Outperform
Baird maintained an Outperform rating on Clym Bio and raised its price target to $25.00 per share from $21.00, per TradingView News/Benzinga.
EQUITY | Sep 03, 2026, 06:12 PM UTC
M
CLYM116 shows deep, durable APRIL suppression; 12-week dosing supported
CLYM116, an anti-APRIL antibody for IgA nephropathy, showed deep and durable APRIL suppression and favorable safety in phase I, with reductions in IgA, Gd-IgA1 and IgM. PK/PD supports 12-week dosing; phase II and III pla
EQUITY | Sep 03, 2026, 01:41 PM UTC
M
Climb Bio reports Phase 1 CLYM116 data with durable suppression
Climb Bio announced Phase 1 data for CLYM116 showing a ~29-day half-life and rapid, durable APRIL and IgA suppression with favorable tolerability.
REGULATION | Sep 03, 2026, 11:53 AM UTC
M
CLYM116 Phase 1 data backs every-12-week dosing plan
Initial Phase 1 results for CLYM116 in healthy volunteers reported robust biomarker suppression, favorable safety, and a long half-life supporting every-12-week dosing; Phase 2 NAVIGATE-2 will confirm ahead of Phase 3.
EQUITY | Sep 03, 2026, 11:48 AM UTC
M
Climb Bio’s CLYM116 Phase 1 supports every-12-week dosing in IgA nephropathy
Phase 1 for CLYM116 showed prolonged half-life, strong APRIL and IgA suppression, and a favorable safety profile, supporting Q12W dosing in IgA nephropathy. Phase 2/3 planned; key data expected in 2027.
EQUITY | Sep 03, 2026, 11:10 AM UTC
M
Climb Bio says CLYM116 Phase 1 data show ~29-day half-life in IgA nephropathy
Single 320 mg CLYM116 dose drove near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression through 12 weeks, with ~29-day half-life. Treatment was generally well-tolerated with no serious AEs, dose-limiting toxi
EQUITY | Sep 03, 2026, 11:08 AM UTC
M
Climb Bio announces CLYM116 Phase 1 data in IgA nephropathy
Climb Bio says CLYM116 Phase 1 data shows prolonged half-life and APRIL suppression supporting every-12-week dosing in IgA nephropathy.
EQUITY | Sep 03, 2026, 11:00 AM UTC
L
Climb Bio to participate in upcoming investor conferences
Climb Bio said members of its executive team will participate in upcoming investor conferences, per the company’s announcement.
EQUITY | Sep 02, 2026, 11:07 AM UTC
L
CLYM - Climb Bio to Present at Upcoming Investor Conferences
CLYM - Climb Bio to Present at Upcoming Investor Conferences
EQUITY | Sep 02, 2026, 11:01 AM UTC
L
CLYM - Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
CLYM - Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
EARNINGS | Aug 06, 2026, 11:01 AM UTC
H
Stocks Rise After Upgrades, Initiations
Select stocks gain after upgrades and initiations
EQUITY | Aug 03, 2026, 11:52 AM UTC
H
RBC Initiates CLYM Outperform
RBC starts CLYM with Outperform rating
EQUITY | Aug 03, 2026, 11:48 AM UTC
M
Analysts Initiate Coverage
Multiple stocks receive new analyst coverage
EQUITY | Aug 03, 2026, 10:58 AM UTC